Delayed onset muscle
soreness (DOMS) is a complex spreading out,
which is related to swelling of muscles, tenderness, rigidity, pain,
disruption of muscle fiber, alteration in the kinematics of joint,
acute tissue damage, and reduction in power and strength. β-Caryophyllene
(BCP), a potent phytocannabinoid, could play an important role in
managing DOMS because of its wide diversity of biological activities,
particularly its anti-inflammatory activity; however, its poor stability
in light, temperature, high volatility, and insolubility can restrict
the medical practices. In this study, liposomal β-caryophyllene
(Rephyll) was designed and established in powder form constructed
by the nanofiber weaving technology to improve the bioavailability
of BCP with improved stability. Rephyll was characterized by Fourier
transform infrared spectroscopy, transmission electron microscopy,
and differential scanning calorimetry studies. Encapsulation efficiency,
loading capacity, and in vitro release studies revealed that Rephyll
can be an auspicious drug delivery arrangement for BCP. The effects
of Rephyll were evaluated by a randomized, double-blinded, crossover-designed,
placebo-controlled study. The oral consumption of Rephyll significantly
reduced the pain visual assessment score, revealing that Rephyll effectively
reduced DOMS with improved recovery without any side effects due to
the bioavailable form of the phytocannabinoid BCP in the liposomal
powder formulation.